Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in JapanGlobeNewsWire • Monday
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused InvestorsGlobeNewsWire • 06/11/26
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney InjuryGlobeNewsWire • 06/05/26
Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology ConferenceGlobeNewsWire • 05/19/26
Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart StudyGlobeNewsWire • 02/24/26
Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewsWire • 02/13/25